{"id":"W2603747793","doi":"10.1200/jco.2013.31.15_suppl.tps4593","title":"A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University of Alberta; University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Pazopanib; Ipilimumab; Sunitinib; Renal cell carcinoma; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Pharmacology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00133996,0.00204869,0.002139472,0.0005725537,0.0005049692,0.001115634,0.001387815,0.001375887,0.004884529],"category_scores_gemma":[0.0008865622,0.0008385289,0.001794041,0.0005145903,0.001315212,0.001179618,0.000408968,0.00382705,0.001139054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001500128,"about_ca_system_score_gemma":0.002184177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002225337,"about_ca_topic_score_gemma":0.005616592,"domain_scores_codex":[0.9995099,0.0002203337,0.00002011342,0.00009802204,0.00003818444,0.0001135045],"domain_scores_gemma":[0.9991562,0.0001149428,0.0001166333,0.0000541995,0.00003580332,0.0005222094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7291242,0.1357934,0.006475447,0.0008853904,0.001417829,0.0004157214,0.0004685619,0.003180342,0.03490728,0.0002964103,0.004228137,0.08280721],"study_design_scores_gemma":[0.5047397,0.4803299,0.008928816,0.00002844019,0.0004022249,0.000237127,0.00007490507,0.0009177206,0.002311594,0.0001925813,0.001807348,0.00002969793],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918187,0.001526778,0.0004031344,0.0004475781,0.0001663493,0.00261384,0.0008884874,0.00008066527,0.002054605],"genre_scores_gemma":[0.9886291,0.001794556,0.00149142,0.0007387866,0.0002140003,0.002499881,0.001939433,0.00003722074,0.002655573],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004884529,"threshold_uncertainty_score":0.01634043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07959710117448439,"score_gpt":0.4098850430227954,"score_spread":0.330287941848311,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}